$3.26
Live
0.92%
Downside
Day's Volatility :5.4%
Upside
4.52%
53.68%
Downside
52 Weeks Volatility :69.25%
Upside
33.6%
Period | Codexis, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -7.34% | 3.6% | 0.0% |
6 Months | 19.23% | 10.2% | 0.0% |
1 Year | 102.98% | 19.6% | 0.0% |
3 Years | -88.14% | 16.8% | -23.0% |
Market Capitalization | 239.0M |
Book Value | $0.87 |
Earnings Per Share (EPS) | -1.1 |
PEG Ratio | -1.16 |
Wall Street Target Price | 6.86 |
Profit Margin | -125.41% |
Operating Margin TTM | -282.83% |
Return On Assets TTM | -19.6% |
Return On Equity TTM | -82.29% |
Revenue TTM | 60.9M |
Revenue Per Share TTM | 0.87 |
Quarterly Revenue Growth YOY | -62.6% |
Gross Profit TTM | 20.5M |
EBITDA | -48.0M |
Diluted Eps TTM | -1.1 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.75 |
EPS Estimate Next Year | -0.73 |
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Next Quarter | -0.19 |
What analysts predicted
Upside of 110.43%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 60.6M | ↑ 21.13% |
Net Income | -10.9M | ↓ 52.7% |
Net Profit Margin | -17.95% | ↑ 28.02% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 68.5M | ↑ 12.98% |
Net Income | -11.9M | ↑ 9.72% |
Net Profit Margin | -17.43% | ↑ 0.52% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 69.1M | ↑ 0.87% |
Net Income | -24.0M | ↑ 101.17% |
Net Profit Margin | -34.77% | ↓ 17.34% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 104.8M | ↑ 51.69% |
Net Income | -21.3M | ↓ 11.37% |
Net Profit Margin | -20.31% | ↑ 14.46% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 138.6M | ↑ 32.3% |
Net Income | -33.6M | ↑ 57.86% |
Net Profit Margin | -24.24% | ↓ 3.93% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 70.1M | ↓ 49.39% |
Net Income | -76.2M | ↑ 126.96% |
Net Profit Margin | -108.69% | ↓ 84.45% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.0M | ↓ 57.26% |
Net Income | -22.6M | ↑ 79.43% |
Net Profit Margin | -174.22% | ↓ 132.72% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 21.3M | ↑ 64.25% |
Net Income | -11.5M | ↓ 49.05% |
Net Profit Margin | -54.04% | ↑ 120.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.3M | ↓ 56.49% |
Net Income | -34.9M | ↑ 202.94% |
Net Profit Margin | -376.29% | ↓ 322.25% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 26.6M | ↑ 186.31% |
Net Income | -7.2M | ↓ 79.4% |
Net Profit Margin | -27.08% | ↑ 349.21% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 17.1M | ↓ 35.72% |
Net Income | -11.5M | ↑ 59.97% |
Net Profit Margin | -67.39% | ↓ 40.31% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 8.0M | ↓ 53.27% |
Net Income | -22.8M | ↑ 97.78% |
Net Profit Margin | -285.19% | ↓ 217.8% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 78.3M | ↑ 45.98% |
Total Liabilities | 22.0M | ↓ 24.42% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 149.1M | ↑ 90.43% |
Total Liabilities | 43.6M | ↑ 98.19% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 221.6M | ↑ 48.68% |
Total Liabilities | 51.5M | ↑ 18.34% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 246.4M | ↑ 11.16% |
Total Liabilities | 82.0M | ↑ 59.07% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 250.4M | ↑ 1.63% |
Total Liabilities | 105.6M | ↑ 28.79% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 136.6M | ↓ 45.46% |
Total Liabilities | 49.9M | ↓ 52.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 218.1M | ↓ 12.91% |
Total Liabilities | 92.1M | ↓ 12.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 206.8M | ↓ 5.19% |
Total Liabilities | 82.6M | ↓ 10.24% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 154.5M | ↓ 25.3% |
Total Liabilities | 62.9M | ↓ 23.82% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 136.6M | ↓ 11.59% |
Total Liabilities | 49.9M | ↓ 20.66% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 149.6M | ↑ 9.52% |
Total Liabilities | 70.3M | ↑ 40.74% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 132.0M | ↓ 11.74% |
Total Liabilities | 70.6M | ↑ 0.38% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.1M | ↑ 60.84% |
Investing Cash Flow | -2.8M | ↑ 204.63% |
Financing Cash Flow | 38.6M | ↑ 78.15% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.6M | ↓ 10.88% |
Investing Cash Flow | -3.7M | ↑ 32.5% |
Financing Cash Flow | 54.0M | ↑ 39.91% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.5M | ↑ 31.08% |
Investing Cash Flow | -5.7M | ↑ 56.83% |
Financing Cash Flow | 80.8M | ↑ 49.75% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.3M | ↓ 13.34% |
Investing Cash Flow | -21.4M | ↑ 272.69% |
Financing Cash Flow | 3.8M | ↓ 95.34% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 11.3M | ↓ 179.09% |
Investing Cash Flow | -13.6M | ↓ 36.62% |
Financing Cash Flow | -575.0K | ↓ 115.26% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.2M | ↓ 287.35% |
Investing Cash Flow | -3.3M | ↓ 10051.52% |
Financing Cash Flow | 1.4M | ↑ 298.82% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.1M | ↑ 74.63% |
Investing Cash Flow | -1.6M | ↓ 52.16% |
Financing Cash Flow | 6.9M | ↑ 412.06% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.3M | ↑ 1.34% |
Investing Cash Flow | -1.1M | ↓ 29.54% |
Financing Cash Flow | -108.0K | ↓ 101.56% |
Sell
Neutral
Buy
Codexis, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Codexis, Inc. | 16.78% | 19.23% | 102.98% | -88.14% | -74.89% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Codexis, Inc. | NA | NA | -1.16 | -0.75 | -0.82 | -0.2 | NA | 0.87 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Codexis, Inc. | Buy | $239.0M | -74.89% | NA | -125.41% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Codexis, Inc.
Revenue is down for the last 3 quarters, 26.56M → 7.97M (in $), with an average decrease of 44.5% per quarter
Netprofit is down for the last 3 quarters, -7.19M → -22.75M (in $), with an average decrease of 78.9% per quarter
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 132.9%
Nantahala Capital Management, LLC
BlackRock Inc
FMR Inc
Vanguard Group Inc
Opaleye Management Inc
Baillie Gifford & Co Limited.
codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop
Organization | Codexis, Inc. |
Employees | 174 |
CEO | Dr. Stephen George Dilly MBBS, Ph.D. |
Industry | Process Industries |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$3.26
-4.4%
Invesco Bulletshares 2025 Hi
$3.26
-4.4%
Schwab International Dividend Equity Etf
$3.26
-4.4%
Blockchain Coinvestors Acquisition Corp.
$3.26
-4.4%
Allgiant Travel Company
$3.26
-4.4%
Rogers Corp
$3.26
-4.4%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$3.26
-4.4%
Iheartmedia
$3.26
-4.4%
Lightpath Technologies Inc
$3.26
-4.4%